Title : Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.

Pub. Date : 2020 Feb

PMID : 31914336






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Currently, several DAA options are available on the market.Areas covered: This review focuses on the pharmacokinetics, efficacy, tolerability and safety profile of DCV-TRIO, a twice-daily fixed-dose combination of daclatasvir, asunaprevir and beclabuvir approved in Japan for the treatment of genotype 1 HCV infection.Expert opinion: The DCV-TRIO combination achieved good response rates in genotype 1 patients (SVR12 >= 95% in naive subtype 1b), independently from IL28B genotype, cirrhotic status and prior interferon exposure. daa trio Rho guanine nucleotide exchange factor Homo sapiens